Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin with Cytarabine and Daunorubicin in AML
NCT00037583Phase 2Completed
- Sponsor
- Pfizer
- Primary completion
- Sep 2003
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Primary endpoints: Maximum Tolerated Dose and Safety Assessment. Status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00037583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037583.